Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Part of paid clinical trials in Norfolk, Virginia.
- Sponsor
- Novartis Pharmaceuticals
- Study ID
- NCT05335876
- Phase
- PHASE3
- Status
- Recruiting
Conditions
- Spinal Muscular Atrophy (SMA)
Eligibility Criteria
- Sex
- ALL
- Age
- 0 Years - 100 Years
- Healthy Volunteers
- Not accepted
Interventions
- onasemnogene abeparvovec — BIOLOGICALOnasemnogene abeparvovec is a non-replicating recombinant adeno-associated virus serotype 9 containing the human survival motor neuron gene under the control of the ytomegalovirus enhancer/chicken β-actin-hybrid promoter. Onasemnogene abeparvovec is administered as a one-time intravenous (IV) infusion or intrathecal (IT) injection. Dosage determined by participant weight.
Study Details
This is a global, prospective, multi-center study that is designed to assess the long-term safety and efficacy of OAV101 in patients who participated in an OAV101 clinical trial. The assessments of safety and efficacy in Study COAV101A12308 will continue for 5 years after enrollment in this study.
Key Dates
- Start date
- Dec 19, 2022
- Status verified
- Jan 2026
- Primary completion
- Sep 26, 2030
- Completion
- Feb 27, 2031
Study Design
- Enrollment
- 175 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- TREATMENT
Arms
- Experimental: Intravenous (IV) & Intrathecal (IT) Onasemnogene AbeparvovecPatients who received OAV101 IT or OAV101 IV in clinical trials (COAV101A12306, COAV101B12301 and COAV101B12302)
Primary Outcome Measure
Number of participants with treatment-emergent serious adverse events (SAEs) [ Time Frame: Up to Year 5 ]
Central Contacts
- Novartis Pharmaceuticals1-888-669-6682
- Novartis Pharmaceuticals+41613241111
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Child Hosp Of The Kings Daughters | Norfolk | Virginia | 23507 | Crystal Proud (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Norfolk, VA
By research site
Related Studies
- Registry of Patients With a Diagnosis of Spinal Muscular Atrophy (SMA)Recruiting · Novartis Pharmaceuticals · Phoenix, Arizona
- A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular AtrophyPHASE2 · Recruiting · argenx · Little Rock, Arkansas
- Diagnostic Journey, Patient Experience, and Disparities in the Treatment of Spinal Muscular Atrophy (SMA) in the MedStar Health SystemRecruiting · Medstar Health Research Institute · Washinton, District of Columbia
- HABIT-ILE + FST in Children With SMA: Preliminary EffectivenessRecruiting · Teachers College, Columbia University · New York, New York